cisplatin or not cisplatin?
 

Hi everybody:

My wife is having Vinorelbine injections for her lung spots, and she is taking Tykerb since last May.
One another oncologist suggests we should have cisplatin combo with the Vinorelbine injection.
Would it be too strong for my wife? Is that combo work ok with Tykerb?
Any experience? Any idea?
Thanks for any reply!

Donald,

Looks like

Navelbin = vinorelbine

I think several of our members have used (or are currently on) the Navelbin + Tykerb combo.

Here's one article I found via PubMed database:

Cancer Treat Rev. 2009 Apr;35(2):121-36. Epub 2008 Nov 12.http://www.ncbi.nlm.nih.gov/corehtml...PubMedLink.gif Links

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

Nielsen DL, Andersson M, Kamby C.
Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. dornie01@heh.regionh.dk

There is strong clinical evidence that trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor (HER) two tyrosine kinase receptor, is an important component of first-line treatment of patients with HER2-positive metastatic breast cancer.

In particular the combination with taxanes and vinorelbine has been established. In the preoperative setting inclusion of trastuzumab has significantly increased the pathological complete response rate. Results from large phase III trials evaluating adjuvant therapy in HER2-positive early breast cancer indicate that the addition of trastuzumab to chemotherapy improves disease-free and overall survival. The use of lapatinib, a dual tyrosine kinase inhibitor of both HER1 and HER2, in combination with capecitabine in the second-line treatment of HER2-positive patients with metastatic breast cancer previously treated with trastuzumab has been established. There is modest, but still insufficient, support that the compound passes the blood-brain barrier. Several trials are ongoing both in the adjuvant and metastatic settings and we have to await the results of these to clarify the role of trastuzumab and lapatinib.

The clinical problem of tumours developing resistance to HER2-directed therapy is becoming increasingly important. Several issues about optimal selection of patients, prevention of resistance and use of different treatment options are still unresolved. In this article, we summarise the current knowledge on clinical evidence of HER2-directed therapy and the potential mechanisms of underlying resistance, including the possible clinical implications and review new therapeutic options.

Hi Jackie07:
As my understanding, Navelbin is the brand name of oral vinorelbine, and it is not the same of injection form of Vinorelbine.
My wife is having injection of Vinorelbine and Tykerb, and I want some opinions about ADDING or NOT ADDING CISPLATIN?
Anyway, thanks for your kindly reply and information!

Donald